Rationale for Categorizing Hydrocodone Combination Products as Schedule III

Published Online: Monday, January 20, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
 
This is the fifth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Because orally administered morphine is associated with a significantly greater number of adverse events, ibuprofen is the better choice for relieving pain in children with broken bones.
Roughly two-thirds of emergency department admissions for overdoses involve prescription opioid medications.
It is compulsory for pharmacists to counsel all patients receiving opioids, evaluate the potential benefit of a naloxone reversal device, and contact the opioid prescriber if such a device is deemed appropriate.
Used alongside antidepressants, OTC analgesics and anti-inflammatories purchased from pharmacies may effectively treat patients with depression without increasing their risk of adverse events.
Latest Issues
$auto_registration$